|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
41,504,000 |
Market
Cap: |
1.35(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$21.06 - $40.91 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 625 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Collegium Pharmaceutical is a pharmaceutical company. Co.'s portfolio includes: Xtampza ER, Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. Xtampza ER was approved by the U.S. Food and Drug Administration for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
137,001 |
244,681 |
382,081 |
1,004,450 |
Total Sell Value |
$4,598,859 |
$7,967,692 |
$11,068,318 |
$25,236,488 |
Total People Sold |
2 |
4 |
5 |
7 |
Total Sell Transactions |
3 |
10 |
15 |
42 |
End Date |
2024-03-01 |
2023-11-29 |
2023-05-31 |
2022-05-31 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Tupper Colleen |
EVP & Chief Financial Officer |
|
2024-05-28 |
4 |
AS |
$34.21 |
$674,368 |
D/D |
(19,710) |
130,845 |
|
- |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2024-05-24 |
4 |
S |
$33.98 |
$1,930,455 |
D/D |
(56,807) |
105,902 |
|
3% |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2024-05-24 |
4 |
OE |
$24.03 |
$571,698 |
D/D |
23,791 |
162,709 |
|
- |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2024-05-23 |
4 |
S |
$33.82 |
$1,732,093 |
D/D |
(51,209) |
138,918 |
|
2% |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2024-05-23 |
4 |
OE |
$24.03 |
$1,230,552 |
D/D |
51,209 |
190,127 |
|
- |
|
Balice-Gordon Rita J. |
Director |
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,693 |
46,488 |
|
- |
|
Santini Gino |
Director |
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,693 |
75,656 |
|
- |
|
Heffernan Michael Thomas |
Director |
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,693 |
45,508 |
|
- |
|
Mcfarlane Neil F. |
Director |
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,693 |
49,365 |
|
- |
|
Bohlin Garen G |
Director |
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,693 |
52,468 |
|
- |
|
Freund John Gordon |
Director |
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,693 |
52,468 |
|
- |
|
Melincoff Gwen A |
Director |
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,693 |
52,468 |
|
- |
|
Fallon John A. |
Director |
|
2024-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,693 |
54,843 |
|
- |
|
Bohlin Garen G |
Director |
|
2024-05-14 |
4 |
S |
$32.30 |
$936,311 |
D/D |
(28,985) |
44,775 |
|
0% |
|
Bohlin Garen G |
Director |
|
2024-05-14 |
4 |
OE |
$5.73 |
$166,084 |
D/D |
28,985 |
73,760 |
|
- |
|
Smith Thomas B |
EVP and Chief Medical Officer |
|
2024-02-29 |
4 |
S |
$36.76 |
$36,580 |
D/D |
(995) |
63,409 |
|
10% |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2024-02-26 |
4 |
AS |
$36.38 |
$364,270 |
D/D |
(10,000) |
138,918 |
|
-6% |
|
Smith Thomas B |
EVP and Chief Medical Officer |
|
2024-02-12 |
4 |
D |
$33.70 |
$107,806 |
D/D |
(3,199) |
64,404 |
|
- |
|
Smith Thomas B |
EVP and Chief Medical Officer |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
35,423 |
67,603 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2024-02-12 |
4 |
D |
$33.70 |
$4,342,818 |
D/D |
(128,867) |
444,867 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
298,734 |
573,734 |
|
- |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2024-02-12 |
4 |
D |
$33.70 |
$1,000,553 |
D/D |
(29,690) |
148,918 |
|
- |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
67,286 |
178,608 |
|
- |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2024-02-12 |
4 |
D |
$33.70 |
$1,070,177 |
D/D |
(31,756) |
164,409 |
|
- |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
76,647 |
196,165 |
|
- |
|
406 Records found
|
|
Page 1 of 17 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|